Share This Page

Support & Insight for the Autumn of Life

Bezisterim: A New Way to Manage Methylation in Dementia

"Alzheimer's Innovations" superimposed on a neuron
Bezisterim can manage inflammation and enhance energy transfer (insulin sensitivity) in the brain. Learn how it is in trials to improve memory and thinking in Alzheimer's. (Video+Article)

A well-known driver of Alzheimer’s is inflammation. Inflammation is often caused by too much methylation (hypermethalation). In clinical trials, the new drug Bezisterim (also known as NE3107) helped keep methylation in balance, measurably reducing inflammation and the cognitive decline it causes.

These results were seen in the analysis of data generated from BioVie’s Phase 3 trial in Alzheimer’s disease (AD). The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.

“We all age and get older – nothing can change that. But these data provide evidence that bezisterim may have the potential to help keep people healthier for a longer time as we age,” said Cuong Do, BioVie’s President and CEO. “BioVie believes that DNA methylation may not need to constantly increase as we age, and thus the progression of age-related disease may not be uni-directional. Bezisterim is believed to be the first drug candidate that has shown in clinical trials the ability to modulate the level of DNA methylation, and do so in a manner that’s correlated with disease.

DNA methylation

DNA methylation is a natural process where methyl groups are added to the surface of DNA, thereby interfering with the body’s natural process for decoding genetic information. DNA methylation accumulates as people age and can be affected by behavioral (diet, exercise) and environmental factors. Hypermethylation of DNA has been associated with dementia, cognitive impairment and other diseases.

Inflammation has been shown to be a driver of hypermethylation of DNA, and the extent of DNA methylation can be measured by various “biological clocks.”

Newly presented data show that patients treated with bezisterim experienced an age deceleration advantage over patients treated with placebo on four biological clocks. Age deceleration is the difference between a person’s biological age as measured by various DNA methylation clocks and their actual age since birth. A lower value is preferable and suggests that the biological age is lower than the actual age. For example, Bezisterim-treated patients saw -4.77 years advantage on the Inflammation Age Clock .

A Different Approach

BioVie, the maker of bezisterim, believes that inflammation is central to the development and progression of Alzheimer’s Disease. BioVie’s different approach focuses on our novel molecule, bezisterim, currently being studied in people diagnosed with Alzheimer’s Disease, and the hypotheses that selective modulation of inflammation, and the enhancement of energy transfer (insulin sensitivity) in the brain, may be able to improve memory and thinking, and may protect against neurodegeneration. If successful, bezisterim may be able to provide future benefit to the millions of people diagnosed with Alzheimer’s, as well as to the families, friends, and professionals who care for them.

NE3107 is Bezisterim

The name “bezisterim” has been approved as the non-proprietary (generic) name for NE3107 by the United States Adopted Names (USAN) Council and World Health Organization (WHO) International Nonproprietary Names (INN) expert committee.

Bezisterim Trials

Bezisterim (NE3107) is being investigated for Alzheimer’s disease (AD). Its manufacturer, BioVie, has conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate AD (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference.

Footnotes

  1. Wang Z Nucleic Acids Research , 2020, Vol. 48, No. 5; Sugden K Neurology 2022;99:e1402-e1413; Tang X DOI: 10.1002/mds.29157; Tabaeia S Artificial Cells, Nanomedicine, and Biotechnology, 47:1, 2031-2041; Qiu W Am J Respir Crit Care Med Vol 185, Iss. 4, pp 373–381, Feb 15, 2012; Rysz C Int. J. Mol. Sci. 2022, 23(13), 7108; Kraiczy J Mucosal Immunology volume 9, pages 647–658 (2016); Rump K Sci Rep 9, 18511 (2019).
  2. Stenvinkel P doi: 10.1111/j.1365-2796.2007.01777.
  3. The Inflammation Age Clock measures the extent of chronic inflammation and predicts the risk of developing age-related disorders. Sayed Nat Aging. 2021 Jul;1:598-615.

Reference

Source

About BioVie Inc.

  • BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD.  For more information, visit http://www.bioviepharma.com/ .
Email me when people comment
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments
Edited by:
Picture of P. Berger

P. Berger

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Related:

Dr. Oliver Sacks
Books

Alzheimer’s & The Power of Music

Music’s effect on the brain fascinated neurologist Oliver Sacks, MD. His research led him to helping people with Alzheimer’s. Watch this best-selling author share how dementia, without exception, responds to music.

Read More »
Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips, Diet

Alzheimer's & Dementia Weekly Newsletter: Free

Free. Care & Treatment. Research & Prevention

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

News to Get at the Truth

Subscribe To Our Weekly Newsletter